Advances in the design and development of SARS-CoV-2 vaccines

Military Medical Research

Zibiao Li¹  Dai-Xu Wei²  Xiao-Hong Zhao²  Xue-Liang Peng²  Ji-Si-Yu Cheng²  Hai-Lun Gong²  Meng-Di Yuan² 

[1]Institute of Materials Research and Engineering, A*STAR (Agency for Science, Technology and Research), 2 Fusionopolis Way, Innovis, #08-03, 138634, Singapore, Singapore

[2]Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Department of Life Sciences and Medicine, Northwest University, 710069, Xi’an, China

关键词: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);    Coronavirus disease 2019 (COVID-19);    Vaccine;    Synthetic biology;    Nanoscience;   

DOI  :  10.1186/s40779-021-00360-1

来源: Springer

【 摘 要 】

Since the end of 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA genome of SARS-CoV-2, which is highly infectious and prone to rapid mutation, encodes both structural and nonstructural proteins. Vaccination is currently the only effective method to prevent COVID-19, and structural proteins are critical targets for vaccine development. Currently, many vaccines are in clinical trials or are already on the market. This review highlights ongoing advances in the design of prophylactic or therapeutic vaccines against COVID-19, including viral vector vaccines, DNA vaccines, RNA vaccines, live-attenuated vaccines, inactivated virus vaccines, recombinant protein vaccines and bionic nanoparticle vaccines. In addition to traditional inactivated virus vaccines, some novel vaccines based on viral vectors, nanoscience and synthetic biology also play important roles in combating COVID-19. However, many challenges persist in ongoing clinical trials.

【 授权许可】

CC BY